Collaborative project with world leader in AI computing demonstrates Artificial workflows and model integration for self-driving generative virtual screening in drug discovery. Company also announces ...

The proof-of-concept demonstrates the power of pairing AI with lab orchestration solutions to automate molecular screening ...

We recently compiled a list of the 8 Best Humane Stocks to Invest in Now. In this article, we are going to take a look at ...

AI development powerhouse Nvidia kicked off this year’s J.P. Morgan Healthcare Conference in San Francisco by announcing new ...

Nvidia Corporation is poised for >70% YoY growth in Q4 FY25, driven by AI dominance and a $300B healthcare opportunity.

the NVIDIA BioNeMo platform running on Certain statements in this press release including, but not limited to, statements as to: the benefits, impact, availability, and performance of NVIDIA’s ...

Illumina will offer its DRAGEN analysis software on Nvidia’s accelerated computing platforms through the next-gen sequencing ...

During the JPMorgan Healthcare Conference in San Francisco, NVIDIA presented its most recent developments in ...

A partnership with biotechnology firm Illumina Inc. aims to unlock insights from genomics data by combining Illumina’s sequencing technology with Nvidia’s AI tools. Nvidia said the collaboration will ...

NVIDIA and Innophore’s collaborative artificial intelligence (AI)-driven, drug safety screening platform CavitOmiX is set to launch in late January 2025, says Innophore CEO Christian Gruber.

The convergence of AI, accelerated computing and biological data is turning healthcare into the largest technology industry. Healthcare leaders IQVIA, Illumina and Mayo Clinic, as well as Arc ...

“Our partnership is going to focus on developing true foundation models for biology using Nvidia BioNeMo and DGX Cloud. All of our resulting work is going to be shared and contributed back to ...